Cosmetic Ingredient Bans Tracker: EU, UK and US Dates, and What Reformulation Costs on the Line
In short: Cosmetic ingredient bans and restrictions take effect on dates set in the act. In the EU, a substance newly classified as carcinogenic, mutagenic or toxic for reproduction (CMR) is moved into Annex II of the Cosmetics Regulation 1223/2009 and banned from the date its classification applies, with no sell-through period. Great Britain adds the same substances later through its own regulations, and the US Modernization of Cosmetics Regulation Act (MoCRA) sets dates for records and labels rather than ingredient bans. This tracker lists each act with its cut-off dates and prices what a reformulation costs on a filling and packing line.
- Open windows on 19 November 2026: EU vitamin A stock may be made available until 1 May 2027 (163 days), Great Britain's TPO stock until 14 February 2027 (87 days), and EU stock labelled under the old fragrance allergen rules until 31 July 2028.
- The EU banned TPO, the photoinitiator in UV gel nail products, from 1 September 2025 by Regulation (EU) 2025/877, published 111 days earlier. The CLP act that classed it as toxic for reproduction was published 605 days earlier. Great Britain bans new placings from 15 August 2026.
- Example plant: switching four leave-on SKUs on one tube and bottle line costs EUR 233,986.20 to EUR 234,425.45. Stock left on the ban date is EUR 111,974.19 of it, the part a sell-through window would have removed.
Tracker, updated 19 November 2026. Next update: December 2026, with the acts published since. Sources are listed at the end.
A cosmetic ingredient ban reaches the plant as a date, and the plant pays for it in line hours, cleans and stock. Plants that run MES for cosmetics manufacturing already hold half the answer to what a reformulation costs: which product ran on which line, at what measured rate, and how long each clean and changeover took. The other half is the act itself: what it bans or limits, from which date, and whether stock already made may still be sold. This page logs those acts each month for the EU, Great Britain and the US, from the legal texts as published, and works through what a switch costs on one filling line.
The reader is a plant, production, quality or regulatory manager at a cosmetics or personal care manufacturer or contract filler. The formula, the safety assessment and the product information file stay with the regulatory and QA teams; this page is about the line time, the cleans and the stock that a new formula takes.
Cosmetic ingredient bans and restrictions by cut-off date, November 2026
Each row is an act read in its published text: EUR-Lex for the EU, legislation.gov.uk for Great Britain, the US Code and the FDA for the US. Two dates matter for stock. The first is the date after which a product that does not comply may no longer be placed on the market, which Article 2 of the Cosmetics Regulation defines as its first making available. The second, where the act gives one, is the date after which it may no longer be made available, meaning any supply for distribution, consumption or use, by anyone in the chain. The gap between them is the sell-through window.
| Where | Act and publication | What changes | No new placings from | No supply at all from | On 19 Nov 2026 |
|---|---|---|---|---|---|
| EU | Regulation (EU) 2026/78 (Omnibus VIII), OJ 13 Jan 2026 | 15 CMR substances added to Annex II (entries 1752 to 1766); silver limited by form; hexyl salicylate capped by product type; o-phenylphenol and its sodium salt as preservatives | 1 May 2026 | 1 May 2026 | In force, no window |
| EU | Regulation (EU) 2025/877 (Omnibus VII), OJ 13 May 2025 | 21 Annex II entries (1731 to 1751), TPO among them; TPO's Annex III entry 311 deleted | 1 Sep 2025 | 1 Sep 2025 | In force, no window |
| EU | Regulation (EU) 2024/996, OJ 4 Apr 2024 | Vitamin A (retinol, retinyl acetate, retinyl palmitate): 0.05% retinol equivalent in body lotion, 0.3% in other products | 1 Nov 2025 | 1 May 2027 | Window open, 163 days left |
| EU | Regulation (EU) 2024/996 | Alpha-arbutin, arbutin, genistein, daidzein, kojic acid (1%, face and hand only) | 1 Feb 2025 | 1 Nov 2025 | Closed |
| EU | Regulation (EU) 2024/996 | Triclocarban and triclosan, Annex V conditions | After 31 Dec 2024 | After 31 Oct 2025 | Closed |
| EU | Regulation (EU) 2024/996 | 4-methylbenzylidene camphor moved to Annex II (entry 1730) | 1 May 2025 | 1 May 2026 | Closed |
| EU | Regulation (EU) 2023/1545, OJ 27 Jul 2023 | Fragrance allergens labelled by name above 0.001% in leave-on and 0.01% in rinse-off products; the list grows from 24 substances with the 56 the SCCS identified | After 31 Jul 2026 | After 31 Jul 2028 | Window open, 620 days left |
| GB | SI 2026/23, made 12 Jan 2026 | TPO and other CMR substances added to Annex 2 (entries 1745 to 1760) | 15 Aug 2026 | After 14 Feb 2027 | Window open, 87 days left |
| GB | SI 2026/23 | 4-methylbenzylidene camphor to Annex 2 (entry 1744); Annex 5 formaldehyde releaser labelling tightened; Annex 6 UV filter entry 18 removed | 15 Jul 2026 | After 14 Jan 2027 | Window open, 56 days left |
| GB | SI 2025/413, made 27 Mar 2025 | Methyl salicylate in Annex 3, with limits by product type | After 30 Sep 2025 | After 31 Mar 2026 | Closed |
| US | MoCRA, enacted 29 Dec 2022 | Facility registration and product listing; serious adverse event reports in 15 business days; safety substantiation records; label contact for adverse events | No ingredient ban | No ingredient ban | In force; rules on GMP and fragrance allergen labels still to come |
Source: the acts linked in the sections below. "After" a date means the act names that date as the last day on which supply is still allowed. Days left are counted from 19 November 2026 to the date shown.
Three readings carry the rest of the page.
- The EU's CMR bans have no sell-through window. Omnibus VII and Omnibus VIII apply one date to new placings and to every unit already in the chain. Stock made the day before the date cannot be sold the day after.
- Restrictions outside the CMR route do get windows. Vitamin A got 576 days to the placing cut-off and 546 more to sell through. The fragrance allergen labels got 1,100 days and then 731.
- The warning comes from chemicals law, not cosmetics law. TPO's classification as toxic for reproduction was published 605 days before the ban applied; the cosmetics act that listed it came 111 days before.
How a CMR classification becomes a cosmetics ban
The mechanism sits in two laws. Under Article 15 of the Cosmetics Regulation (EC) No 1223/2009, substances classified as CMR in category 1A or 1B are prohibited in cosmetic products. Use by way of exception needs every condition the article sets: compliance with food safety rules, no suitable alternative substances as documented in an analysis of alternatives, a request for a particular product category with known exposure, and a finding of safety by the Scientific Committee on Consumer Safety (SCCS). Category 2 substances are prohibited unless the SCCS has evaluated them and found them acceptable. The Commission has to amend the annexes within 15 months of the substance's inclusion in Part 3 of Annex VI to the CLP Regulation (EC) No 1272/2008, the EU's list of harmonised classifications.
TPO shows the sequence. Commission Delegated Regulation (EU) 2024/197, adopted 19 October 2023 and published 5 January 2024, classified diphenyl(2,4,6-trimethylbenzoyl)phosphine oxide as Repr. 1B and Skin Sens. 1B, applying from 1 September 2025. Commission Regulation (EU) 2025/877, published 13 May 2025, added it to Annex II as entry 1731 and deleted the Annex III entry 311 that had allowed it in professional artificial nail systems at up to 5%. Its recital 11 says the amendments should apply from the same date as the classifications. Recital 5 records that no request for use by way of exception had been submitted for the substances concerned.
The Commission's own questions and answers on TPO in nail products, dated 7 August 2025, state the consequence for stock: from 1 September 2025 both placing and making available of products containing TPO are prohibited, and the Cosmetics Regulation contains no sell-through or use-up provision for CMR 1A or 1B substances. A nail technician cannot use such a product on clients from that date, even one bought before it. Ireland's regulator, the HPRA, told distributors on 29 July 2025 not to supply any product containing TPO from 1 September and told salons to stop using such products and dispose of them.
| Step | Act or text | Date | Days before the ban applied |
|---|---|---|---|
| 1. Harmonised classification published | CLP Delegated Regulation (EU) 2024/197 | 5 Jan 2024 | 605 |
| 2. Cosmetics annex amended | Regulation (EU) 2025/877 | 13 May 2025 | 111 |
| 3. National regulator notice | HPRA news item | 29 Jul 2025 | 34 |
| 4. Commission questions and answers | DG GROW page on TPO | 7 Aug 2025 | 25 |
| 5. Classification and ban apply | Both acts | 1 Sep 2025 | 0 |
For a plant, the working date is step 1. The cosmetics act at step 2 carries no new decision for a 1B substance with no exception request; it writes into Annex II what the classification already settled. A plant that starts its reformulation at step 2 has 111 days for supplier changes, trials, stability, artwork and running down stock. A plant that starts at step 1 has 605.
Placed on the market or made available: the two dates that decide what old stock is worth
Outside the automatic CMR route, the Commission writes transition periods into the annex entries, and they come as a pair. Regulation (EU) 2024/996, adopted 3 April 2024, limited vitamin A to 0.05% retinol equivalent in body lotion and 0.3% in other leave-on and rinse-off products. Products that do not comply may not be placed on the Union market from 1 November 2025, and may not be made available from 1 May 2027. The same act gave alpha-arbutin, arbutin, genistein, daidzein and kojic acid a shorter pair: 1 February 2025 and 1 November 2025.
The fragrance allergen act is the longest. Regulation (EU) 2023/1545, published 27 July 2023, requires named labelling of further fragrance allergens when a substance exceeds 0.001% in leave-on products or 0.01% in rinse-off products. Its recitals note that 24 allergens were labelled individually and that the SCCS had identified 56 more. Products that do not comply could be placed on the market until 31 July 2026 and may be made available until 31 July 2028. The change is a label change, but a label is a statement about a formula: every product whose fragrance carries one of the added allergens above the threshold needs new artwork, and the print runs on hand go to waste if they outlast the window.
| Act | Publication to the placing cut-off | Sell-through after it | What a plant can do with old stock |
|---|---|---|---|
| 2025/877 and 2026/78, CMR bans | 111 and 108 days | 0 days | Nothing; it is unsellable from the date, in the plant and in the chain |
| 2024/996, kojic acid group | 303 days | 273 days | Ship before the placing cut-off; the chain sells it through |
| 2024/996, vitamin A | 576 days | 546 days | Same, with a longer run to build the new formula |
| 2023/1545, allergen labels | 1,100 days | 731 days | Use up printed packaging before the placing cut-off |
| GB SI 2026/23, TPO | 215 days from the date made | 183 days | Ship to Great Britain before 15 Aug 2026; sold through until 14 Feb 2027 |
Source: the acts' own dates; days counted from the EU Official Journal publication or the date the GB instrument was made.
The placing cut-off is the plant's deadline, because the plant is where a product is placed on the market. The making-available date is the chain's deadline, and it decides how much stock the plant can still ship in the last weeks before the placing cut-off. A window of 546 days means a full warehouse on the placing date is not a loss. A window of zero means it is.
Great Britain: the same substances on a later clock
Since leaving the EU, Great Britain amends its retained version of Regulation 1223/2009 by statutory instrument, and the dates differ from the EU's. The Cosmetic Products Regulation (EC) No 1223/2009 (Restriction of Chemical Substances) (Amendment and Transitional Provisions) Regulations 2026, SI 2026/23, were made on 12 January 2026 and laid on 15 January. They add TPO to Annex 2 as entry 1745, with entries 1746 to 1760 for other CMR substances including clothianidin, tetrabromobisphenol-A, dibutyltin oxide, S-metolachlor and trimethyl borate, from 15 August 2026. A product placed on the market before 15 August 2026 that contains one of them may be made available until the end of 14 February 2027. From 15 July 2026 the same instrument moves 3-(4'-methylbenzylidene) camphor into Annex 2 as entry 1744, removes it from the UV filters in Annex 6 and changes the Annex 5 labelling rule for preservatives that release formaldehyde; products placed before 15 July 2026 may be made available until the end of 14 January 2027.
The earlier instrument, SI 2025/413, made 27 March 2025, put methyl salicylate into Annex 3 from 30 September 2025 with a limit for each product type, from 0.002% in eye make-up and make-up remover to 2.5% in toothpaste. Products placed on the market by 30 September 2025 could be made available until the end of 31 March 2026.
The duties behind the dates are set out in the Office for Product Safety and Standards (OPSS) guidance making cosmetic products available to consumers in Great Britain. Each product needs a Responsible Person with a UK address, a notification to OPSS before it is made available, and a product information file kept in English for 10 years after the last batch is made available. The file includes the safety report and evidence of good manufacturing practice, so each reformulated product brings a new or revised file before its first GB shipment.
United States: MoCRA dates are about records, not bans
MoCRA, enacted on 29 December 2022, bans no ingredient. Its dates, written into 21 U.S.C. 364 to 364j, set what a manufacturer has to keep and report:
| Provision | Section | Date in the statute | Status on the FDA page |
|---|---|---|---|
| Facility registration | 364c(a)(1)(A) | Not later than 1 year after enactment: 29 Dec 2023 | Required; renewed every two years |
| Product listing with ingredients | 364c | With registration | Required; updates provided annually |
| Serious adverse event reports | 364a | In force | Within 15 business days; records kept 6 years, 3 for qualifying small businesses |
| Safety substantiation records | 364d(a) | No date | Records supporting safety kept by the responsible person |
| Label contact for adverse event reports | 364e(a) | 2 years after enactment: 29 Dec 2024 | In force |
| Fragrance allergens on the label | 364e(b) | Proposed rule within 18 months: 29 Jun 2024 | Listed as a requirement still to be set by regulation |
| Good manufacturing practice rule | 364b(c) | Proposed within 2 years, final within 3: 29 Dec 2024 and 29 Dec 2025 | Draft guidance on cosmetic GMP linked |
| Asbestos testing for talc products | Pub. L. 117-328, sec. 3505 | Proposed rule within 1 year | Proposed December 2024, withdrawn November 2025 |
Source: the statute on govinfo (2023 edition) and the FDA's MoCRA page, content current as of 29 October 2026, which also lists the FDA's report on PFAS in cosmetic products, published 29 December 2025, and its final guidance on mandatory cosmetic recalls, announced 29 October 2026. The FDA's registration and listing page gives the worked case of a registration received on 20 February 2024 being renewed by 20 February 2026.
For a plant that fills for the US and the EU, the effect is one formula question and two record questions. The ingredient decision follows the EU or GB act. The US listing has to change when the ingredient list changes, at the next annual update, and the safety substantiation record has to cover the new formula from its first US shipment. Once the fragrance allergen rule is published, it becomes a third label clock beside the EU's 2028 date.
Case notes from regulators, newest first
Each note ends with what its own text tells a plant to check. New acts and regulator releases are added at the top with their dates.
OPSS product safety report, 20 August 2026 (PSD 2607-0164): a banned fragrance ingredient and three unlabelled allergens
The OPSS report concerns an anti-dandruff shampoo made in India and sold online in Great Britain, in all bottle sizes. Testing found butylphenyl methylpropional, which the report says is not permitted in cosmetic products, and three fragrance allergens not declared on the label above the 100 mg/kg threshold for rinse-off products: citronellol at 187 mg/kg, linalool at 195 mg/kg and alpha-isomethyl ionone at 188 mg/kg. Local authority Trading Standards notified it, the risk is rated serious, and the import was rejected at the border.
- All four findings sit in the fragrance. Butylphenyl methylpropional is a fragrance ingredient, and the report names the other three as allergenic fragrances. A reformulation check that reads only the brand's own formula sheet, and not the fragrance supplier's composition, misses all four.
- 187 mg/kg against 100 mg/kg is a label failure, not a safety limit. The allergens were legal to use and illegal to leave off the label. When the fragrance changes, the label changes with it, and 100 mg/kg is 0.01%, the same rinse-off threshold the EU uses in 2023/1545.
EU Omnibus VIII, published 13 January 2026, applied 1 May 2026: 108 days, hexyl salicylate capped
Regulation (EU) 2026/78, adopted 12 January 2026, added entries 1752 to 1766 to Annex II, among them a photoinitiator (CAS 119344-86-4), acetone oxime, trimethyl borate, S-metolachlor and pyraclostrobin, and merged perboric acid and its salts into entry 1397. Silver is banned as nano and massive forms and allowed as a powder between 100 nm and 1 mm, at up to 0.05% in toothpaste and mouthwash and, as colourant CI 77820, up to 0.2% in lip products and eye shadow. Hexyl salicylate, a fragrance ingredient, enters Annex III as entry 380 with limits by product type: 2% in hydroalcoholic fragrances, 0.5% in rinse-off and 0.3% in leave-on products, 0.1% in the listed children's products, and 0.001% in toothpaste and mouthwash. The act gives no transitional provision. The HPRA's page on Omnibus VIII says it draws no distinction between placing and making available, and that products that do not comply must be removed from the market before 1 May.
- One fragrance, two answers. A fragrance dosed so that each product carries 0.4% hexyl salicylate would pass in a shower gel (0.5% rinse-off) and fail in a body lotion (0.3% leave-on). The reformulation list is drawn by product type, so only the leave-on SKUs go to trial.
- 108 days from publication to application. Any trial, stability or compatibility work on a new fragrance had to fit between 13 January and 1 May 2026, unless it began when the substances were classified under CLP.
GB SI 2026/23, made 12 January 2026: TPO 348 days after the EU
The GB instrument bans new placings of TPO products from 15 August 2026, 348 days after the EU date, and lets products placed before then be made available until 14 February 2027. For 348 days the same gel nail product could be placed in Great Britain and not in the EU, and from 15 August 2026 GB stock still has 183 days of sell-through that EU stock never had.
- A plant shipping to both markets ran two legal dates for one product. A TPO formula could still go to Great Britain after 1 September 2025 while the EU version had to be TPO-free. Two formulas on one line means two artworks and a full clean between them.
- The GB sell-through ends on 14 February 2027. Stock placed in Great Britain before 15 August 2026 has 87 days left from 19 November 2026; after that it is in the same position as EU stock in September 2025.
Commission questions and answers, 7 August 2025, and HPRA notice, 29 July 2025: no use-up for stock already bought
Both texts came after the act and before its date, 25 and 34 days ahead. The Commission's answers rule out a reading that stock bought before 1 September 2025 could still be used in salons, and say that the 2015 SCCS opinion on professional UV-cured gels predates the new classification. They also note that a proposal to revise the Cosmetics Regulation has been tabled, and that the current law applies until it is adopted.
- The customer's stock is the manufacturer's problem too. With no use-up, units sitting at a distributor or a salon on 1 September could not be sold or used, so returns and credit notes can follow the date back to the filler.
- A guidance date is not a start date. Both releases came within five weeks of the ban; neither changed it.
Case: TPO in gel nail products, the EU in September 2025 and Great Britain in August 2026
TPO is the one substance on this page with a full trail in both jurisdictions, and its dates show what a reformulation has to fit inside.
| Date | EU | Great Britain |
|---|---|---|
| 5 Jan 2024 | CLP act 2024/197 classes TPO Repr. 1B, applying 1 Sep 2025 | |
| 13 May 2025 | 2025/877 lists TPO in Annex II, entry 1731; Annex III entry 311 (up to 5%, professional nail systems) deleted | |
| 1 Sep 2025 | Placing and making available prohibited; salons may not use stock | TPO products still placed |
| 12 Jan 2026 | SI 2026/23 made: TPO to Annex 2, entry 1745 | |
| 15 Aug 2026 | No new placings of TPO products | |
| 14 Feb 2027 | Last day TPO products placed before 15 Aug 2026 may be made available |
Source: the four acts and the Commission's questions and answers. Three things set this case apart from the others on the page.
- The exception was there to take, and no one asked. Article 15(2) allows a 1B substance by exception with an analysis of alternatives and an SCCS finding. Recital 5 of 2025/877 says no such request was submitted. Where a plant depends on a substance that has been classified, whether its suppliers or a trade association are preparing an exception request is a question to ask in the first month after the CLP publication, not the last.
- The substance had an Annex III entry, so plants were set up around it. TPO was allowed up to 5% in professional artificial nail systems. A product category built on a permitted restriction lost it in one act, with 111 days of notice in the cosmetics text and 605 in the classification.
- A photoinitiator is not swapped like a fragrance. Curing under a lamp depends on it, so the trial is a performance test as well as a stability test. Omnibus VIII then banned another photoinitiator (CAS 119344-86-4) from 1 May 2026, so a replacement chosen in 2025 had to be checked again against the 2026 list.
Book a demo and see OEE and losses per line and shift.
Worked example: four leave-on SKUs reformulated on one tube and bottle line
Example plant. Every operating figure in this section is Example data; the margin ratios are sourced. The plant is not any firm named above.
The Example plant is an EU personal care filler. Its Line 3 fills tubes and bottles on two shifts, five days a week. Four leave-on SKUs use a fragrance compound that contains a substance newly classified Repr. 1B. As with TPO, the cosmetics act will apply from the classification date with no sell-through, so on that day every old-formula unit in the plant and in its customers' warehouses becomes unsellable. The fragrance supplier delivers a replacement compound; the regulatory team updates the formulas, the safety assessments and the product information files. Line 3 has to fill trial batches, switch between old and new formula with full cleans while both are in demand, and change the printed packs, because the ingredient list on each pack names the old fragrance components.
The margin ratio. The plant enters the selling price and margin of each SKU. For this example the margin is anchored to Eurostat's structural business statistics for NACE C20.42, manufacture of perfumes and toilet preparations, EU27, 2021 to 2024: value added was 30.48% (2023) to 33.39% (2021) of the value of output, and the gross operating rate, after labour, 13.02% to 14.07%. Value added is what the plant keeps over bought-in goods and services, so here a unit not sold loses its bought-in cost, 66.61% to 69.52% of its ex-works price, and a line hour taken from saleable output loses its value added. The worked rows use the lower ratio, 30.48%; the totals are repeated at 33.39%.
| SKU | Product | Ex-works price | Measured rate on Line 3 | Units a week | Value added a unit (30.48%) | Value added a line hour |
|---|---|---|---|---|---|---|
| A | Body lotion, 400 ml pump bottle | EUR 3.15 | 1,530 an hour | 7,860 | EUR 0.96012 | EUR 1,468.98 |
| B | Body lotion, 200 ml tube | EUR 2.18 | 2,275 an hour | 14,140 | EUR 0.664464 | EUR 1,511.66 |
| C | Hand cream, 75 ml tube | EUR 1.74 | 2,940 an hour | 9,930 | EUR 0.530352 | EUR 1,559.23 |
| D | After-sun lotion, 200 ml bottle | EUR 2.42 | 1,895 an hour | 3,170 | EUR 0.737616 | EUR 1,397.78 |
Example data; ratio from Eurostat. A: 3.15 x 0.3048 = 0.96012; 1,530 x 0.96012 = 1,468.98. B: 2.18 x 0.3048 = 0.664464; 2,275 x 0.664464 = 1,511.66. C: 1.74 x 0.3048 = 0.530352; 2,940 x 0.530352 = 1,559.23. D: 2.42 x 0.3048 = 0.737616; 1,895 x 0.737616 = 1,397.78. The rate is the one the line record measured when each product ran on Line 3, not the nameplate speed.
Step 1: trial batches. Each new formula is filled in trial batches on Line 3 for stability, packaging compatibility and pump or tube function. The trial units are not sold, so they lose their bought-in cost, and each trial takes 1.4 hours of line time from saleable output. Trial batch sizes are 348.4 kg (A), 338 kg (B), 327 kg (C) and 355.8 kg (D), filled at 0.40, 0.20, 0.075 and 0.20 kg a unit.
| SKU | Trials | Units filled | Bought-in cost lost | Line hours | Value added lost |
|---|---|---|---|---|---|
| A | 2 | 2 x 871 = 1,742 | EUR 3,814.77 | 2.8 | EUR 4,113.14 |
| B | 3 | 3 x 1,690 = 5,070 | EUR 7,683.77 | 4.2 | EUR 6,348.97 |
| C | 3 | 3 x 4,360 = 13,080 | EUR 15,822.20 | 4.2 | EUR 6,548.77 |
| D | 4 | 4 x 1,779 = 7,116 | EUR 11,971.84 | 5.6 | EUR 7,827.57 |
| Total | 12 | 27,008 | EUR 39,292.58 | 16.8 | EUR 24,838.45 |
Example data. Bought-in cost at 69.52% of price: 1,742 x 3.15 x 0.6952 = 3,814.77; 5,070 x 2.18 x 0.6952 = 7,683.77; 13,080 x 1.74 x 0.6952 = 15,822.20; 7,116 x 2.42 x 0.6952 = 11,971.84. Line hours: 2.8 x 1,468.98 = 4,113.14; 4.2 x 1,511.66 = 6,348.97; 4.2 x 1,559.23 = 6,548.77; 5.6 x 1,397.78 = 7,827.57.
Step 2: extra changeovers and cleans. While customers still take the old formula and the new one is built up ahead of the date, Line 3 runs both. A change between two products of the same formula family takes a short clean; a change from old to new formula takes a full clean with verification, 2.8 hours, so that no banned substance carries over into the new product. The number of full cleans depends on how often each SKU has to alternate.
| SKU | Full cleans, old to new | Line hours | Value added lost |
|---|---|---|---|
| A | 2 | 5.6 | EUR 8,226.29 |
| B | 4 | 11.2 | EUR 16,930.59 |
| C | 3 | 8.4 | EUR 13,097.53 |
| D | 2 | 5.6 | EUR 7,827.57 |
| Total | 11 | 30.8 | EUR 46,081.98 |
Example data. 5.6 x 1,468.98 = 8,226.29; 11.2 x 1,511.66 = 16,930.59; 8.4 x 1,559.23 = 13,097.53; 5.6 x 1,397.78 = 7,827.57. Cleaning agents, water and labour are not priced. The line hours are priced at value added only where Line 3 is the constraint; on a line with spare hours, the cost is the labour and the cleaning materials.
Step 3: the stock left on the date. The run-down in the ERP aimed at zero old stock on the date. Demand ran ahead of the forecast in the last month, the new formula reached the shelves later than expected, and two weeks of old formula remained in the plant's warehouse and its customers' distribution centres. Under a CMR ban none of it can be supplied.
| SKU | Units left (2 weeks) | Bought-in cost lost |
|---|---|---|
| A | 15,720 | EUR 34,424.91 |
| B | 28,280 | EUR 42,859.36 |
| C | 19,860 | EUR 24,023.61 |
| D | 6,340 | EUR 10,666.31 |
| Total | 70,200 | EUR 111,974.19 |
Example data. 15,720 x 3.15 x 0.6952 = 34,424.91; 28,280 x 2.18 x 0.6952 = 42,859.36; 19,860 x 1.74 x 0.6952 = 24,023.61; 6,340 x 2.42 x 0.6952 = 10,666.31. Disposal, returns handling and the customers' own costs are not priced.
Step 4: labels and artwork. The ingredient list required by Article 19(1)(g) of the Cosmetics Regulation names each ingredient in descending order of weight, so a new fragrance compound means a new list on every pack. Each SKU needs new artwork and proofs, EUR 600 a SKU, and the printed packaging on hand with the old list is scrapped: 22,000 labels for A at EUR 0.04, 41,300 printed tubes for B at EUR 0.12, 35,500 printed tubes for C at EUR 0.09 and 9,200 labels for D at EUR 0.04.
Example data. Printed packs: 22,000 x 0.04 = 880.00; 41,300 x 0.12 = 4,956.00; 35,500 x 0.09 = 3,195.00; 9,200 x 0.04 = 368.00; total 9,399.00. Artwork: 4 x 600 = 2,400.00.
Step 5: add it up.
| Cost | A | B | C | D | Total |
|---|---|---|---|---|---|
| Trial units, bought-in cost | 3,814.77 | 7,683.77 | 15,822.20 | 11,971.84 | 39,292.58 |
| Trial line hours | 4,113.14 | 6,348.97 | 6,548.77 | 7,827.57 | 24,838.45 |
| Extra full cleans | 8,226.29 | 16,930.59 | 13,097.53 | 7,827.57 | 46,081.98 |
| Stock left on the date | 34,424.91 | 42,859.36 | 24,023.61 | 10,666.31 | 111,974.19 |
| Printed packs scrapped | 880.00 | 4,956.00 | 3,195.00 | 368.00 | 9,399.00 |
| Artwork and proofs | 600.00 | 600.00 | 600.00 | 600.00 | 2,400.00 |
| Total at 30.48%, EUR | 52,059.11 | 79,378.69 | 63,287.11 | 39,261.29 | 233,986.20 |
| Total at 33.39%, EUR | 51,636.56 | 79,485.57 | 63,494.98 | 39,808.34 | 234,425.45 |
Example data. A: 3,814.77 + 4,113.14 + 8,226.29 + 34,424.91 + 880.00 + 600.00 = 52,059.11. B: 7,683.77 + 6,348.97 + 16,930.59 + 42,859.36 + 4,956.00 + 600.00 = 79,378.69. C: 15,822.20 + 6,548.77 + 13,097.53 + 24,023.61 + 3,195.00 + 600.00 = 63,287.11. D: 11,971.84 + 7,827.57 + 7,827.57 + 10,666.31 + 368.00 + 600.00 = 39,261.29. Total 233,986.20. At 33.39% the same steps give bought-in cost at 66.61% and line hours at the higher value added, for a total of 234,425.45, of which the stock left on the date is 107,287.13.
Step 6: read the result. Of EUR 233,986.20, the stock left on the date is EUR 111,974.19, or 47.86%; at the higher ratio it is EUR 107,287.13 of EUR 234,425.45, or 45.77%. That half of the bill is set by the act, not by the line: under a vitamin A style window of 546 days, the same stock would have sold through and the bill would have been EUR 122,012.01 to EUR 127,138.32. The line's part is 47.6 hours of Line 3, 16.8 for trials and 30.8 for cleans, a little over half a week of its 80 shift hours. Every hour of it is priced at the measured rate of the product that would otherwise have run.
Three caveats. Value added is above contribution margin, because it still has to pay for labour, so a line hour priced at value added is an upper bound for a line that is not the constraint. Testing, stability studies, the safety assessor's time and the fragrance supplier's charges are not priced. And the stock figure depends on two weeks of cover on the date, which is the number the run-down is meant to drive to zero.
Which SKU to reformulate first: margin, line time and the date
With line hours scarce, the four SKUs cannot all switch in the same week. Two numbers from the example rank them, and they disagree.
| SKU | Value added a week (30.48%) | Value added a year | Line hours to switch | Value added a year per switch hour | Rank by weekly value | Rank by switch hour |
|---|---|---|---|---|---|---|
| A | EUR 7,546.54 | EUR 392,420.25 | 8.4 | EUR 46,716.70 | 2 | 1 |
| B | EUR 9,395.52 | EUR 488,567.09 | 15.4 | EUR 31,725.14 | 1 | 2 |
| C | EUR 5,266.40 | EUR 273,852.56 | 12.6 | EUR 21,734.33 | 3 | 3 |
| D | EUR 2,338.24 | EUR 121,588.62 | 11.2 | EUR 10,856.13 | 4 | 4 |
Example data. A: 7,860 x 0.96012 = 7,546.54 a week; x 52 = 392,420.25; 2.8 + 5.6 = 8.4 h; 392,420.25 / 8.4 = 46,716.70. B: 14,140 x 0.664464 = 9,395.52; 488,567.09; 4.2 + 11.2 = 15.4 h; 31,725.14. C: 9,930 x 0.530352 = 5,266.40; 273,852.56; 4.2 + 8.4 = 12.6 h; 21,734.33. D: 3,170 x 0.737616 = 2,338.24; 121,588.62; 5.6 + 5.6 = 11.2 h; 10,856.13. At 33.39% the weekly values are EUR 8,267.03, 10,292.53, 5,769.19 and 2,561.48, and the order does not change.
| Approach | Choose it if | Anchor on this page | Watch for |
|---|---|---|---|
| Switch first the SKU with the highest value per switch hour | Line hours are the limit and the date is far off | A: EUR 46,716.70 a year per switch hour, 8.4 hours | A large SKU with a high clean count left to the end, when the date is close |
| Switch first the SKU with the highest value a week | The date is close, so each week late strands stock | B: EUR 9,395.52 a week, and the top stock line, EUR 42,859.36 | B's four full cleans, 11.2 hours, crowd out the others |
| Delist or merge the smallest SKU instead of reformulating | Its yearly value does not carry its trials and cleans | D: EUR 10,856.13 a year per switch hour, four trials | Customers who buy D with A and B; the delisting decision sits with sales |
| Build the new formula ahead and stop the old one early | The act gives no sell-through, as for CMR bans | Stock left on the date: EUR 111,974.19, 47.86% of the bill | Warehouse space and the new formula's shelf life |
| Run old and new side by side to the last day | The act gives a long making-available window, as for vitamin A | 546 days after the placing cut-off | Full cleans between formulas on every alternation |
The two rankings answer different questions. Value per switch hour says which reformulation repays the line time best. Value per week says which one costs more for each week it is late. With 605 days of notice from a CLP publication, the first ranking leads; with 108 days from a cosmetics act, the second does. A link to the volume side of the same choice is in SKU rationalization with line data, and the same "the act sets the date" logic applied to food batches is in EUDR for food manufacturers.
Questions to put in writing to a supplier of line data or MES software before a reformulation:
- Is the measured rate of each product on each line available from the record, not only the nameplate speed?
- Are cleans and changeovers logged as their own stop types, with their duration, so a full clean between formulas can be told apart from a short clean?
- Can trial runs be marked as trials, so their line time is counted and kept out of the saleable output?
- With the selling price and margin of each SKU entered, are the line hours of a trial or a clean priced in money?
- How does the line record join the product codes in the ERP, so the old and new formula of one SKU appear as two products?
This week and this quarter, by role
A new CLP publication, an annex change or a GB instrument starts the same list. Each step produces a number the next step uses.
This week: regulatory affairs lead
- Read the newest CLP delegated act's list of substances against every formula and every fragrance supplier's composition statement, and mark each hit with the act's application date.
- For each hit, write down which route applies: a CMR 1A or 1B ban with no window, or a restriction with a placing and a making-available date.
- List the products also sold in Great Britain and the US, with the GB instrument's dates and the next US listing update.
This week: plant and production manager
- For each affected SKU, take the measured rate on its line from the last three months of runs, not the nameplate speed.
- From the stop log, take the time of a full clean and of a short clean on that line, so the cost of alternating formulas rests on the line's own numbers. CIP time in OEE covers how to count cleaning time without hiding it.
This quarter: production and supply chain
- Rank the affected SKUs by value per switch hour and by value per week, as in the example, and agree which ranking leads given the date.
- Set the run-down of old stock in the ERP so the plant and its customers hold zero old formula on a CMR ban date, and check it weekly against what the line actually filled.
- Book trial runs on the line as trials, so the first-off checks and the line time are both recorded. First-off approval after changeover covers the check on the first good units.
This quarter: packaging and artwork
- Count printed packs on hand and on order for each affected SKU, and cut reorders so the stock of old artwork runs out with the old formula.
- Prepare the new ingredient lists, including the fragrance allergens named under 2023/1545, so one artwork change covers both acts where they meet.
Fill weights and changeover times differ by format, and changeover time sets out how to measure the parts of a change that grow with every extra formula on the line.
What the line record adds to a reformulation file
A reformulation file holds the new formula, the safety assessment, the stability results and the label. The line record adds what the switch cost: the measured rate of each product when it ran, the hours of each trial, each full clean and each changeover, and the output that was not made during them. Those numbers price the line's part of the bill and show, week by week, whether the run-down of old formula is on course for the date.
Fabrico is a cloud OEE and light MES platform. It shows OEE and losses by machine, line and shift, with data from the machine's PLC or a Fabrico IoT device, and operators give the reason for a stop at the machine. With the selling price and margin of each SKU entered, losses are priced in money. The line record shows which product ran on which line, at what measured rate, and how long each clean, changeover and trial took. On manual stations, AI cameras (an add-on) count output. The formula, the batch records, the safety assessment and the product information file stay in the plant's QA and regulatory systems, and the run-down of stock lives in the ERP, an APS or a spreadsheet. Cosmetics plants can see how this fits in MES for cosmetics manufacturing, in cosmetics manufacturing software and in the comparison of OEE software for cosmetics and personal care manufacturing; the building blocks are OEE software and a light MES.
Book a demo and see OEE and losses per line and shift.
What people ask next
What is a CMR substance in cosmetics?
A substance classified as carcinogenic, mutagenic or toxic for reproduction under the CLP Regulation. Under Article 15 of the Cosmetics Regulation 1223/2009, category 1A and 1B substances are prohibited in cosmetic products unless an exception is granted, which needs an analysis of alternatives and a finding of safety by the SCCS. Category 2 substances are prohibited unless the SCCS has evaluated them and found them acceptable.
Is there a sell-through period when the EU bans a cosmetic ingredient?
Not for CMR 1A or 1B substances. The Commission's questions and answers on TPO, dated 7 August 2025, say the Cosmetics Regulation has no sell-through or use-up provision for them, so placing and making available stop on the same date. Restrictions outside that route carry two dates: vitamin A under Regulation (EU) 2024/996 may not be placed on the market from 1 November 2025 and may not be made available from 1 May 2027.
When was TPO banned in nail products in the EU and in Great Britain?
In the EU from 1 September 2025, by Regulation (EU) 2025/877, with no sell-through and no use of salon stock. In Great Britain, SI 2026/23 bans new placings from 15 August 2026, and products placed before then may be made available until the end of 14 February 2027.
What is the difference between placing on the market and making available?
Under Article 2 of the Cosmetics Regulation, making available is any supply of a cosmetic product for distribution, consumption or use on the market, paid or free, and placing on the market is the first making available. So placing happens once, where the product is first supplied, and making available covers every later supply by distributors and retailers. An act that gives two dates lets stock placed before the first date sell through until the second.
What does MoCRA require of cosmetics manufacturers, and by when?
Facility registration by 29 December 2023, renewed every two years, product listing with ingredients updated annually, serious adverse event reports within 15 business days, safety substantiation records, and a label contact for adverse events from 29 December 2024. The statute also calls for rules on good manufacturing practice and fragrance allergen labelling; the FDA's MoCRA page lists both as still to be set by regulation, with draft GMP guidance.
How much does reformulating a cosmetic product cost on the filling line?
It depends on trial batches, extra full cleans between old and new formula, stock left when the act applies, and scrapped printed packs. In the Example plant on this page, four leave-on SKUs cost EUR 233,986.20 to EUR 234,425.45 to switch on one line, and the stock left on a CMR ban date is EUR 107,287.13 to EUR 111,974.19 of it.
Sources
All sources accessed on 18 November 2026. Dates are adoption, publication, release or content dates where a page gives one; other dates are labelled as what they are.
- Commission Regulation (EU) 2025/877 on certain CMR substances in cosmetic products (EUR-Lex), adopted 12 May 2025, OJ 13 May 2025
- Commission Regulation (EU) 2026/78 on certain CMR substances in cosmetic products, Omnibus VIII (EUR-Lex), adopted 12 January 2026, OJ 13 January 2026
- Commission Regulation (EU) 2024/996 amending Regulation (EC) No 1223/2009 (EUR-Lex), adopted 3 April 2024, OJ 4 April 2024
- Commission Regulation (EU) 2023/1545 on the labelling of fragrance allergens in cosmetic products (EUR-Lex), adopted 26 July 2023, OJ 27 July 2023
- Commission Delegated Regulation (EU) 2024/197 amending the CLP Regulation (EUR-Lex), adopted 19 October 2023, OJ 5 January 2024
- Regulation (EC) No 1223/2009 on cosmetic products, Articles 11, 15 and 19 (EUR-Lex), OJ 22 December 2009
- European Commission, DG GROW: TPO in nail products, questions and answers, 7 August 2025
- Health Products Regulatory Authority (Ireland): TPO added to European Union list of prohibited ingredients, 29 July 2025
- Health Products Regulatory Authority (Ireland): Omnibus Act VIII, new substances restricted or prohibited in cosmetics from May 2026, no page date; covers Regulation (EU) 2026/78
- SI 2026/23, The Cosmetic Products Regulation (EC) No 1223/2009 (Restriction of Chemical Substances) (Amendment and Transitional Provisions) Regulations 2026 (legislation.gov.uk), made 12 January 2026
- SI 2025/413, The Cosmetic Products (Restriction of Chemical Substances) Regulations 2025 (legislation.gov.uk), made 27 March 2025
- Office for Product Safety and Standards: Making cosmetic products available to consumers in Great Britain (GOV.UK), published 4 October 2021
- Office for Product Safety and Standards: Product safety report PSD 2607-0164, anti-dandruff shampoo (GOV.UK), 20 August 2026
- U.S. Food and Drug Administration: Modernization of Cosmetics Regulation Act of 2022 (MoCRA), content current as of 29 October 2026
- U.S. Food and Drug Administration: Registration and Listing of Cosmetic Product Facilities and Products, content current as of 9 September 2026
- 21 U.S.C. 364 to 364j, cosmetics (U.S. Government Publishing Office, govinfo, 2023 edition), 2023 edition
- Eurostat: Enterprise statistics by size class and NACE activity (sbs_ovw_act), C20.42 manufacture of perfumes and toilet preparations, EU27, annual data 2021 to 2024
Related articles

Real Fabrico tiles, sample data.






